Oppenheimer Reaffirms Their Buy Rating on CalciMedica (CALC)

CalciMedica reports Q3 net loss of $7.8 mln

CalciMedica Q3 EPS $(0.52) Misses $(0.42) Estimate

CalciMedica Launches Phase 2 KOURAGE Trial of Auxora in Acute Kidney Injury with Respiratory Failure

CalciMedica Reports Preclinical Success for CRAC Channel Inhibitor in Pulmonary Arterial Hypertension

CalciMedica Q3 Operating Expenses USD 5.618 Million

CalciMedica Q3 Basic EPS USD -0.52

CalciMedica Inc - Cash Position Expected to Fund Operations Into 2H 2026

CalciMedica Reports Auxora Improves Kidney Function in Preclinical AKI Study

CalciMedica Inc expected to post a loss of 41 cents a share - Earnings Preview

CalciMedica Boosts Stock Offering to $9.7 Million

CalciMedica and Telperian Announce AI Collaboration to Enhance Auxora Clinical Trial Analysis

CalciMedica Inc.'s Chief Business Officer Eric W. Roberts Reports Acquisition of Common Shares

CalciMedica’s CBO Makes Bold Stock Purchase!

Eric W. Roberts, Chief Business Officer, Reports Acquisition of CalciMedica Inc. Common Shares

Eric W. Roberts, Chief Business Officer, Acquires Common Shares of CalciMedica Inc

Eric W. Roberts, Chief Business Officer of CalciMedica Inc., Reports Acquisition of Common Shares

Eric W. Roberts, Chief Business Officer, Reports Acquisition of Common Shares in CalciMedica Inc

CalciMedica Inc.'s Chief Medical Officer Sudarshan Hebbar Reports Acquisition of Common Shares

CalciMedica Inc. Chief Business Officer Eric W. Roberts Reports Acquisition of Common Shares